MSD (Merck & Co) has achieved a significant regulatory and commercial victory with the US Food and Drug Administration (FDA) approval of Lipfendra (enlicitide), marking a pivotal moment in cardiovascular medicine and for the pharmaceutical giant’s strategic repositioning. This approval introduces the first-ever oral PCSK9 inhibitor to the market, offering a once-daily pill option for adults grappling with high cholesterol, including those with the inherited condition heterozygous familial hypercholesterolemia (HeFH). The introduction of Lipfendra is not merely a scientific breakthrough; it represents a critical step in MSD’s broader strategy to reduce its substantial revenue reliance on the blockbuster oncology drug Keytruda (pembrolizumab) as its patent exclusivity approaches expiration.
The FDA’s endorsement of Lipfendra is for its use in conjunction with diet and exercise to effectively reduce low-density lipoprotein cholesterol (LDL-C), often referred to as "bad" cholesterol. Until now, the highly effective class of PCSK9 inhibitors has been exclusively available in injectable forms, posing challenges for patient adherence and convenience. MSD’s innovation transforms this landscape, providing a more accessible and potentially more widely adopted treatment option for millions of patients at high risk of cardiovascular events. This strategic move positions MSD as a frontrunner in the evolving cardiometabolic disease market, a therapeutic area poised for significant growth and innovation.
A New Era for Cholesterol Management: The Rise of Oral PCSK9 Inhibition
Lipfendra’s approval heralds a new era in the management of hypercholesterolemia, a condition affecting an estimated 86 million US adults aged 20 or older, according to the US Centers for Disease Control and Prevention (CDC). High LDL-C levels are a primary driver of atherosclerotic cardiovascular disease (ASCVD), leading to the dangerous buildup of plaque in blood vessels, which significantly increases the risk of heart attacks and strokes. While lifestyle modifications and existing medications like statins and ezetimibe form the cornerstone of treatment, many patients, particularly those with genetic predispositions like HeFH, require more potent cholesterol-lowering therapies.
PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibitors represent one of the most powerful advancements in lipid-lowering therapy in recent decades. This class of drugs works by blocking the PCSK9 protein, which typically degrades LDL receptors on liver cells. By inhibiting PCSK9, these drugs allow the liver to recycle more LDL receptors, thereby enhancing its ability to clear LDL-C from the bloodstream. Until Lipfendra, leading PCSK9 inhibitors such as Amgen’s Repatha (evolocumab) and Regeneron/Sanofi’s Praluent (alirocumab) were administered via subcutaneous injections, typically every two to four weeks. While highly effective, the injectable nature of these treatments can be a barrier for some patients due to needle aversion, inconvenience, or the perception of medical complexity, potentially impacting long-term adherence.
The transition from injectable to oral administration for a PCSK9 inhibitor is a monumental leap. It not only addresses a significant unmet need for patient convenience but also has the potential to expand the reach of this highly efficacious therapy to a broader patient population. For patients who struggle with injectable medications or prefer oral options, Lipfendra offers a compelling alternative that could lead to improved treatment persistence and, consequently, better cardiovascular outcomes.
Clinical Validation and Competitive Edge
The FDA’s approval of Lipfendra is underpinned by robust data from MSD’s comprehensive Phase III clinical program. Two pivotal trials, NCT05952856 and NCT05952869, demonstrated the drug’s efficacy and safety profile. In one study (NCT05952856), Lipfendra achieved a remarkable 56% reduction in LDL-C compared to placebo, with this figure rising to an impressive 60% when accounting for negligible baseline levels. A separate trial (NCT05952869) further corroborated these findings, showing a 59% reduction in LDL-C compared to placebo. Beyond direct cholesterol reduction, the trials also indicated additional benefits associated with reducing atherosclerotic cardiovascular disease (ASCVD) risk, a crucial endpoint for cardiovascular therapies. The safety profile of Lipfendra was generally comparable to placebo, although some adverse events, specifically diarrhea and dizziness, were observed at slightly higher rates in one of the studies. These results firmly establish Lipfendra as a highly effective agent in the cholesterol-lowering armamentarium.
MSD’s success with Lipfendra also marks a significant victory in the competitive race to develop an oral PCSK9 inhibitor. The company has effectively outpaced rivals, most notably AstraZeneca, which is still advancing its own oral PCSK9 inhibitor candidate, laroprovstat, through Phase III clinical trials. Being the first to market with an oral formulation provides MSD with a considerable first-mover advantage, allowing it to establish market dominance and capture a substantial share of the patient population seeking this convenient treatment option. This competitive edge is invaluable in the crowded and fiercely contested pharmaceutical landscape.
Expert Reactions and Patient Impact
The approval of Lipfendra has been met with enthusiasm from patient advocacy groups and medical professionals. Katherine Wilemon, CEO of the non-profit Family Heart Foundation, commented, “We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.” This sentiment reflects a broader recognition within the medical community of the importance of offering diverse and accessible treatment modalities to patients.
For patients, particularly those with chronic conditions like hypercholesterolemia, the convenience of a once-daily oral tablet cannot be overstated. Managing chronic diseases often involves long-term medication adherence, which can be challenging with injectable therapies. The psychological and practical barriers associated with self-injecting can lead to missed doses or early discontinuation of treatment, compromising therapeutic efficacy. An oral option simplifies the treatment regimen, potentially leading to higher compliance rates and, consequently, more consistent and effective cholesterol management. This could translate into fewer cardiovascular events and improved quality of life for millions.
MSD’s Strategic Pivot: Sharpening the Post-Keytruda Strategy
The approval of Lipfendra is more than just a win in cardiovascular medicine; it is a cornerstone of MSD’s meticulously crafted "post-Keytruda strategy." Keytruda (pembrolizumab), MSD’s immuno-oncology blockbuster, has been an unprecedented commercial success, transforming cancer treatment and generating colossal revenues for the company. For three consecutive years, it held the title of the world’s top-selling medication, with peak sales reaching an astounding $31.7 billion in 2025 before being recently surpassed by Eli Lilly’s weight-loss drug Mounjaro (tirzepatide).
However, the impending loss of exclusivity for Keytruda, with its core US patent set to expire in late 2028 and other regions following thereafter, presents MSD with a formidable challenge: a looming revenue hole that could significantly impact its financial performance. To mitigate this risk, MSD has embarked on an aggressive diversification strategy, focusing on both in-house research and development (R&D) and strategic business development through mergers and acquisitions (M&A).
Lipfendra represents a significant success of MSD’s internal R&D pipeline in a therapeutic area outside oncology. The company has previously touted the substantial commercial opportunity presented by an oral PCSK9 inhibitor, though specific sales forecasts from MSD itself have not yet been publicly disclosed. However, independent analyses, such as that by GlobalData (the parent company of Pharmaceutical Technology), project robust global sales of $3.5 billion for Lipfendra by 2032, underscoring its potential as a major new growth driver.
Alongside its internal innovation, MSD has been actively bolstering its pipeline through targeted acquisitions. In July 2025, the company announced the acquisition of Verona Pharma, a respiratory disease drug developer, for $10 billion. This was followed by the $9.2 billion buyout of antiviral specialist Cidara Therapeutics in November 2025, aimed at strengthening its infectious disease portfolio. These strategic investments are designed to build a diversified portfolio of high-value assets across multiple therapeutic areas, thereby spreading risk and ensuring sustained growth beyond Keytruda.
Citi analysts, in a research note, echoed this strategic view, stating, “We see Lipfendra as an important addition to MSD’s broader effort to diversify growth drivers and build greater exposure in cardiometabolic disease as Keytruda loss of exclusivity approaches.” This external validation underscores the criticality of Lipfendra to MSD’s long-term financial health and strategic direction. The company is actively building a robust foundation of innovative medicines in high-need areas, ensuring its resilience and leadership in the global pharmaceutical market.
Broader Implications and Future Outlook
The market entry of Lipfendra is expected to have far-reaching implications. It could disrupt the existing market for injectable PCSK9 inhibitors by offering a more patient-friendly alternative. While Repatha and Praluent have established strong market positions, the convenience factor of an oral pill could sway prescribing patterns and patient preferences, potentially leading to a shift in market share. Furthermore, the increased accessibility of a PCSK9 inhibitor could lead to a broader uptake of this potent therapy, especially among patients who might have previously hesitated due to the injectable nature of available options. This could translate into a net benefit for public health by reducing the overall burden of cardiovascular disease.
Beyond its immediate impact on cholesterol management, the success of cholesterol-lowering therapies is also sparking interest in their potential role in other disease areas. For instance, Dutch-based biotech NewAmsterdam Pharma’s cholesterol-lowering therapy obicetrapib, which targets the Cholesteryl Ester Transfer Protein (CETP), has been linked to a decrease in a key biomarker of Alzheimer’s disease. This intriguing finding suggests that drugs designed to clear cholesterol could have therapeutic benefits in neurodegenerative diseases, opening up new avenues for research and development. While Lipfendra’s primary indication is cholesterol reduction, the broader scientific exploration into the systemic effects of lipid modulation highlights the expanding potential of this field.
As MSD prepares for the commercial launch of Lipfendra, considerations around pricing, market access, and educational initiatives will be paramount. Ensuring that this innovative therapy is accessible to the patients who need it most, while also securing a return on investment for MSD, will be a delicate balance. The company will likely invest heavily in physician education and patient support programs to facilitate the smooth integration of Lipfendra into clinical practice.
In conclusion, MSD’s FDA approval for Lipfendra is a landmark achievement that redefines the landscape of cholesterol management with the first oral PCSK9 inhibitor. This not only offers a significant advancement in patient care through enhanced convenience and potential adherence but also serves as a critical pillar in MSD’s strategic effort to diversify its revenue streams and secure its future growth in the post-Keytruda era. The ripple effects of this approval will undoubtedly be felt across the pharmaceutical industry, influencing future drug development, market dynamics, and ultimately, improving the lives of millions worldwide grappling with high cholesterol.
